In this first-in-human clinical trial a novel generator (INTELLAPULSE), designed and built by Stockert, which supports highly flexible PFA protocols as well as RF interventions will be used. For 12 months and follow-up for 12 months, after a 3-months blanking period 50 consecutive paroxysmal AF patients, eligible for catheter ablation, will be enrolled.
new onset atrial fibrillation
age <18 years
previous left atrial ablation
lack or withdrawal of written informed consent
unable to receive ablation therapy
University Hospital Freiburg
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Sponsor institution